Literature DB >> 1510141

Production of angiotensins I and II at tissue sites in intact pigs.

A H Danser1, M M Koning, P J Admiraal, L M Sassen, F H Derkx, P D Verdouw, M A Schalekamp.   

Abstract

To estimate the contribution of angiotensin (ANG) I and II production at tissue sites to the circulating levels, ANG I and II and their radiolabeled counterparts were measured in arterial and venous plasma across various vascular beds during constant infusion of 125I-ANG I into the left cardiac ventricle of anesthetized pigs. In the combined systemic vascular beds, ANG I production was closely correlated with plasma renin activity (PRA) and ANG II production was greater than in the lungs. In the lungs virtually no ANG I but 31% of ANG II in venous plasma was derived from de novo production, which could be fully accounted for by conversion of circulating ANG I. In myocardium, head, skin, skeletal muscle, and kidney, respectively, 40, 58, 55, 67, and 94% of venous ANG I, and 32, 49, 40, 59, and 85% of venous ANG II were derived from de novo production. In these extrapulmonary beds part of de novo produced ANG I and II appeared not to be generated, respectively, by PRA and by conversion of circulating ANG I. These results indicate that production of ANG I at tissue sites contributes to its circulating level and that some circulating ANG II may not be derived from circulating ANG I.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510141     DOI: 10.1152/ajpheart.1992.263.2.H429

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

Authors:  Martin P Schuijt; René de Vries; Pramod R Saxena; Maarten A D H Schalekamp; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Local renin-angiotensin systems.

Authors:  A H Danser
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 3.  Is there an internal cardiac renin-angiotensin system?

Authors:  A H Danser; M A Schalekamp
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 4.  Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease.

Authors:  Keith G Avin; Ranjani N Moorthi
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

5.  Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

Authors:  J P van Kats; L M Sassen; A H Danser; M P Polak; L K Soei; F H Derkx; M A Schalekamp; P D Verdouw
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  The influence of the ACE ( I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus.

Authors:  P T Luik; K Hoogenberg; M N Kerstens; B J Beusekamp; P E De Jong; R P F Dullaart; G J Navis
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

7.  PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

8.  Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control.

Authors:  Alberto Pignone; Angela Del Rosso; K Bridget Brosnihan; Federico Perfetto; Riccardo Livi; Ginevra Fiori; Serena Guiducci; Marina Cinelli; Veronica Rogai; Alessio Tempestini; Francesca Bartoli; Sergio Generini; Carlos M Ferrario; Marco Matucci Cerinic
Journal:  Ann Rheum Dis       Date:  2007-03-14       Impact factor: 19.103

9.  Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.

Authors:  L S Zisman; W T Abraham; G E Meixell; B N Vamvakias; R A Quaife; B D Lowes; R L Roden; S J Peacock; B M Groves; M V Raynolds
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.